(NASDAQ: HYFT) Mindwalk Holdings's forecast annual revenue growth rate of 38.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.66%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.31%.
Mindwalk Holdings's revenue in 2026 is $14,794,927.On average, 4 Wall Street analysts forecast HYFT's revenue for 2026 to be $799,813,902, with the lowest HYFT revenue forecast at $737,316,902, and the highest HYFT revenue forecast at $856,679,711. On average, 3 Wall Street analysts forecast HYFT's revenue for 2027 to be $1,213,383,418, with the lowest HYFT revenue forecast at $1,165,841,386, and the highest HYFT revenue forecast at $1,249,109,177.
In 2028, HYFT is forecast to generate $1,850,862,054 in revenue, with the lowest revenue forecast at $1,778,302,759 and the highest revenue forecast at $1,905,281,525.